TESARO Inc. (TSRO) Drops 5.67% on January 15

Equities Staff |

TESARO Inc. (TSRO) was one of the Russell 2000's biggest losers for Friday January 15 as the stock slid 5.67% to $35.11, a loss of $-2.11 per share. Starting at an opening price of $35.50 a share, the stock traded between $34.03 and $36.08 over the course of the trading day. Volume was 374,709 shares over 5,523 trades, against an average daily volume of 563,020 shares and a total float of 40.09 million.

The losses send TESARO Inc. down to a market cap of $1.41 billion. In the last year, TESARO Inc. has traded between $66.95 and $33.21, and its 50-day SMA is currently $48.40 and 200-day SMA is $52.73.

Tesaro Inc is an oncology-focused biopharmaceutical company engaged in improving the lives of cancer patients. The Company is developing three clinical-stage product candidates including rolapitant, niraparib and TSR-011.

TESARO Inc. is based out of Waltham, MA and has some 275 employees. Its CEO is Leon O. Moulder.

For a complete fundamental analysis analysis of TESARO Inc., check out Equities.com’s Stock Valuation Analysis report for TSRO. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Emerging Growth

Beleave Inc.

Beleave Inc is a biotech company. The Company is engaged in the production of medical marijuana under the Marihuana for Medical Purposes Regulations outlined by Health Canada.

Private Markets


Trustify provides trust and safety in both the digital and physical worlds through our vast network of on-demand Private Investigators.By removing the large retainers and high hourly rates that traditional…


Pinterest is a visual discovery and planning tool. Users ("Pinners") use the site and apps to get ideas for their future, such as recipes, places to travel, and products to…